| Literature DB >> 29271915 |
Yingzi Liu1, Xiuqin Yang2, Xiaoyan Jing3, Xinmiao He4, Liang Wang5, Yang Liu6, Di Liu7,8.
Abstract
The Min pig (Sus scrofa) is a well-known indigenous breed in China. One of its main advantages over European breeds is its high meat quality. Additionally, different cuts of pig also show some different traits of meat quality. To explore the underlying mechanism responsible for the differences of meat quality between different breeds or cuts, the longissimus dorsi muscle (LM) and the biceps femoris muscle (BF) from Min and Large White pigs were investigated using transcriptome analysis. The gene expression profiling identified 1371 differentially expressed genes (DEGs) between LM muscles from Min and Large White pigs, and 114 DEGs between LM and BF muscles from the same Min pigs. Gene Ontology (GO) enrichment of biological functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that the gene products were mainly involved in the IRS1/Akt/FoxO1 signaling pathway, adenosine 5'-monophosphate-activated protein kinase (AMPK) cascade effects, lipid metabolism and amino acid metabolism pathway. Such pathways contributed to fatty acid metabolism, intramuscular fat deposition, and skeletal muscle growth in Min pig. These results give an insight into the mechanisms underlying the formation of skeletal muscle and provide candidate genes for improving meat quality. It will contribute to improving meat quality of pigs through molecular breeding.Entities:
Keywords: Min pig; biceps femoris; longissimus dorsi; meat quality; transcriptomics
Mesh:
Year: 2017 PMID: 29271915 PMCID: PMC5795972 DOI: 10.3390/ijms19010021
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Number of single-end 100 bp clean reads obtained and percentages of mapped reads per individual.
| Group | Individual | Clean Reads | % Mapped Reads | Q20 (%) |
|---|---|---|---|---|
| LW_LM | LW_LM1 | 30,149,804 | 87.49 | 98.01 |
| LW_LM2 | 30,149,790 | 85.72 | 98.15 | |
| LW_LM3 | 30,149,412 | 86.25 | 97.36 | |
| Min_LM | Min_LM1 | 30,149,856 | 85.95 | 97.81 |
| Min_LM2 | 30,149,510 | 86.74 | 98.03 | |
| Min_LM3 | 30,149,878 | 84.95 | 97.83 | |
| Min_BF | Min_BF1 | 30,080,960 | 82.82 | 97.53 |
| Min_BF2 | 30,122,758 | 81.22 | 97.64 | |
| Min_BF3 | 30,455,930 | 84.11 | 98.14 |
Figure 1(a) The density plot of genes’ log10 (FPKM) distribution visualized by CummeRbund. The X-axis represents the log10 (FPKM) of all the genes. The Y-axis represents the genes’ distribution density. The nine groups were shown by different colors; (b) The histogram of gene expression. The X-axis represents individual sample. The Y-axis represents the number of expressed genes. The color depth represents the expression level of genes.
Figure 2Volcano plot for differentially expressed genes (DEGs). The X-axis represents the log2 (FPKM) of all the genes. The Y-axis represents –log10 (p value). Red represents up-regulate DEGs. Blue represents down-regulate DEGs. Grey represents no-DEGs. (a) DEGs of Group LM; (b) DEGs of Group Min.
Figure 3Pheatmaps for DEGs. The X-axis represents samples. The Y-axis represents DEGs. The color depth represents –log10 (FPKM). Red represents up-regulate DEGs. Blue represents down-regulate DEGs. (a) DEGs of Group LM; (b) DEGs of Group Min.
Figure 4Real-time PCR validation of the DEGs analyzed by RNA-seq. (a) 13 genes that were identified as DEGs in Group LM; (b) 8 genes that were identified as DEGs in Group Min. The Y-axis shows the relative expression levels.
Figure 5The column diagrams for Gene Ontology (GO) analysis of DEGs. The X-axis represents the functions of GO analysis. The Y-axis represents the numbers of DEGs. Red represents up-regulate DEGs. Blue represents down-regulate DEGs. (a) DEGs of Group LM; (b) DEGs of Group Min.
Figure 6The column diagrams for Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of DEGs. The X-axis represents the numbers of DEGs. The Y-axis represents the functions of pathways. Each color represents the appropriate biological process. (a) DEGs of Group LM; (b) DEGs of Group Min.
Figure 7The diagrams for the enrichment degree of pathways. The X-axis represents the value of rich factors (the ratio of annotated DEGs to all genes of enriched pathway). The Y-axis represents the names of pathways. The color depth of each point represents q value. The size of each point represents the number of DEGs. (a) Enrichment degree of Group LM; (b) Enrichment degree of Group Min.
Pathways enriched in Group LM.
| Pathway | ||
|---|---|---|
| Insulin resistance | 1.53 × 10−10 | 4.59 × 10−8 |
| Starch and sucrose metabolism | 7.09 × 10−6 | 1.06 × 10−3 |
| Regulation of actin cytoskeleton | 4.09 × 10−5 | 3.96 × 10−3 |
| Insulin signaling pathway | 5.28 × 10−5 | 3.96 × 10−3 |
| PPAR signaling pathway | 8.21 × 10−5 | 4.82 × 10−3 |
| Regulation of lipolysis in adipocytes | 1.07 × 10−4 | 4.82 × 10−3 |
| Adipocytokine signaling pathway | 1.12 × 10−4 | 4.82 × 10−3 |
| Glucagon signaling pathway | 1.46 × 10−4 | 4.97 × 10−3 |
| Bladder cancer | 1.49 × 10−4 | 4.97 × 10−3 |
| PI3K-Akt signaling pathway | 2.20 × 10−4 | 6.60 × 10−3 |
| Pathways in cancer | 2.81 × 10−4 | 7.51 × 10−3 |
| Complement and coagulation cascades | 3.01 × 10−4 | 7.51 × 10−3 |
| Platelet activation | 3.63 × 10−4 | 7.63 × 10−3 |
| MAPK signaling pathway | 3.67 × 10−4 | 7.63 × 10−3 |
| MicroRNAs in cancer | 3.82 × 10−4 | 7.63 × 10−3 |
| Circadian rhythm | 6.99 × 10−4 | 1.27 × 10−2 |
| Amoebiasis | 7.21 × 10−4 | 1.27 × 10−2 |
| AMPK signaling pathway | 9.67 × 10−4 | 1.46 × 10−2 |
| Small cell lung cancer | 9.72 × 10−4 | 1.46 × 10−2 |
| FoxO signaling pathway | 9.74 × 10−4 | 1.46 × 10−2 |
| Proteoglycans in cancer | 1.62 × 10−3 | 2.32 × 10−2 |
| Focal adhesion | 2.19 × 10−3 | 2.89 × 10−2 |
| Riboflavin metabolism | 2.22 × 10−3 | 2.89 × 10−2 |
| Rap1 signaling pathway | 2.36 × 10−3 | 2.95 × 10−2 |
| ECM-receptor interaction | 2.96 × 10−3 | 3.44 × 10−2 |
| Cocaine addiction | 2.98 × 10−3 | 3.44 × 10−2 |
| Hypertrophic cardiomyopathy (HCM) | 3.50 × 10−3 | 3.88 × 10−2 |
| Carbohydrate digestion and absorption | 4.85 × 10−3 | 5.20 × 10−2 |
| Pertussis | 6.19 × 10−3 | 6.40 × 10−2 |
| Protein digestion and absorption | 6.48 × 10−3 | 6.48 × 10−2 |
Pathways enriched in Group Min.
| Pathway | ||
|---|---|---|
| Focal adhesion | 1.74 × 10−6 | 3.05 × 10−4 |
| Pertussis | 9.30 × 10−5 | 5.45 × 10−3 |
| Protein digestion and absorption | 9.58 × 10−5 | 5.45 × 10−3 |
| Amoebiasis | 1.44 × 10−4 | 5.45 × 10−3 |
| ECM-receptor interaction | 1.55 × 10−4 | 5.45 × 10−3 |
| PI3K-Akt signaling pathway | 6.42 × 10−4 | 1.68 × 10−2 |
| Prion diseases | 7.24 × 10−4 | 1.68 × 10−2 |
| AGE-RAGE signaling pathway in diabetic complications | 7.65 × 10−4 | 1.68 × 10−2 |
| Complement and coagulation cascades | 1.10 × 10−3 | 2.14 × 10−2 |
| Platelet activation | 1.45 × 10−3 | 2.55 × 10−2 |
| Staphylococcus aureus infection | 2.54 × 10−3 | 4.06 × 10−2 |
| Regulation of actin cytoskeleton | 3.36 × 10−3 | 4.92 × 10−2 |
| Carbohydrate digestion and absorption | 5.37 × 10−3 | 7.00 × 10−2 |
| Vascular smooth muscle contraction | 5.57 × 10−3 | 7.00 × 10−2 |
| Salmonella infection | 9.99 × 10−3 | 1.17 × 10−1 |
| Oxytocin signaling pathway | 1.21 × 10−2 | 1.27 × 10−1 |
| Phenylalanine metabolism | 1.23 × 10−2 | 1.27 × 10−1 |
| MicroRNAs in cancer | 1.37 × 10−2 | 1.34 × 10−1 |
| Butanoate metabolism | 1.56 × 10−2 | 1.45 × 10−1 |
| Thyroid hormone signaling pathway | 2.02 × 10−2 | 1.78 × 10−1 |
| Pathogenic Escherichia coli infection | 2.20 × 10−2 | 1.84 × 10−1 |
| EGFR tyrosine kinase inhibitor resistance | 2.42 × 10−2 | 1.86 × 10−1 |
| Axon guidance | 2.43 × 10−2 | 1.86 × 10−1 |
| Leukocyte transendothelial migration | 2.77 × 10−2 | 2.03 × 10−1 |
| Glycine, serine and threonine metabolism | 3.22 × 10−2 | 2.27 × 10−1 |
| Tyrosine metabolism | 3.46 × 10−2 | 2.34 × 10−1 |
| Insulin secretion | 3.70 × 10−2 | 2.41 × 10−1 |
| Fat digestion and absorption | 4.76 × 10−2 | 2.91 × 10−1 |
Primer sequences for the real-time PCR amplification of the differential expressed genes.
| Gene | Primer Sequences (5′-3′) | Product Size (bp) | Tm (°C) |
|---|---|---|---|
| F: ACAAGCCATAGTCTTAACGAAA; | 198 | 60 | |
| F: ACTGTCTGGGCAAACCAAAC; | 176 | 60 | |
| F: TAAATCGCAGCCTACCTCCCCT; | 198 | 60 | |
| F: TGCCTGACCAGCAAGACCATC; | 168 | 60 | |
| F: GACGTGGTGAAGGTTCGATT; | 330 | 60 | |
| F: GACCCTCTCACCATTACTTCA; | 121 | 60 | |
| F: CCCAGTATGCCAGGGAGAT; | 125 | 60 | |
| F: CCTGTCACTTTCGAGGCG; | 168 | 60 | |
| F: CCGAGACCGCAGATCTCAAG; | 128 | 60 | |
| F: GATGTGTCGCCTTCTTGTTC; | 93 | 60 | |
| F: GCTTCCCCTGCAACCAATT; | 75 | 60 | |
| F: TCCACAAGTCAAGTCCTCTAATG; | 108 | 60 | |
| F: CGACCGACGCTTTGCTAATA; | 97 | 60 | |
| F: CTACTCGGGCCTCTTCTGTG; | 112 | 60 | |
| F: CTTCCTTTATGGGGCCCTCC; | 181 | 60 | |
| F: GAGCAGAACAAGGAGGCCAT; | 104 | 60 | |
| F: AATGGCTCCACCAATCCAGG; | 102 | 60 | |
| F: CGTGCACTGAGCTCTTCAGG; | 115 | 60 | |
| F: CCAAACATGCTCGCAGATCG; | 150 | 60 | |
| F: GCCTTTCTCCTGGTGTACTGT; | 193 | 60 | |
| F: GGCTCTCACCGGCAGTATTT; | 114 | 60 | |
| F: GCCTCCATTCCCTATCCTGC; | 145 | 60 |